Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female outpatients 18-65 years of age~Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:~* Subjects who completed participation in the Double-blind Randomization Phase (i.e. Week 14 visit) in Trial 331-10-227, Trial 331-10-228, or Trial 331-12-282 or~* Subjects who met criteria for a response, but did not meet criteria for remission at Week 14 of either trial~Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:~• Subjects who completed the last scheduled visit of the prior Double-blind Randomized Phase 3 trial.~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving OPC-34712.~* Subjects with a major protocol violation during the course of their participation in the Double-blind Randomization Phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- OPC-34712 (Brexpiprazole) and Escitalopram (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
- OPC-34712 and Fluoxetine (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
- OPC-34712 and Paroxetine CR (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
- OPC-34712 and Sertraline (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
- OPC-34712 and Duloxetine (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
- OPC-34712 and Venlafaxine XR (Type: EXPERIMENTAL): OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).